SMMT
HEALTHCARESummit Therapeutics Inc
$17.85+0.31 (+1.77%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SMMT Today?
No stock-specific AI insight has been generated for SMMT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$13.83$30.98
$17.85
Fundamentals
Market Cap$13.9B
P/E Ratio—
EPS$-1.59
Dividend Yield—
Dividend / Share—
ROE-2.7%
Profit Margin—
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding776.2M
SMMT News
22 articles- SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackYahoo Finance·May 4, 2026
- Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways247 Wall St·May 4, 2026
- We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash WiselyYahoo Finance·May 4, 2026
- Roblox, Spotify, And Robinhood Are Among Top 10 Large-Cap Losers Last Week (April 27-May 1): Are The Others In Your Portfolio?Benzinga·May 3, 2026
- This is why Summit Therapeutics (SMMT) is one of the Best Stocks to buy in a Rising MarketYahoo Finance·May 2, 2026
- Merck's Biggest Looming Rival In Cancer Just Took A Gut PunchYahoo Finance·May 1, 2026
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBiopharmadive·May 1, 2026
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026Yahoo Finance·Apr 30, 2026
- IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?Benzinga·Apr 19, 2026
- SMMT Stock Up 24% in Three Months: Here's What You Need to KnowYahoo Finance·Apr 16, 2026
- A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA FilingYahoo Finance·Mar 28, 2026
- Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA Filing - What's ChangedYahoo Finance·Mar 28, 2026
- Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?Yahoo Finance·Mar 27, 2026
- Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026Yahoo Finance·Mar 27, 2026
- What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30Yahoo Finance·Mar 26, 2026
- Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 UpdatesYahoo Finance·Mar 26, 2026
- Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool·Mar 25, 2026
- Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price SwingsYahoo Finance·Mar 3, 2026
- Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical InvestmentYahoo Finance·Mar 3, 2026
- Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of IvonescimabYahoo Finance·Mar 2, 2026
- Summit Therapeutics to Present at Upcoming Investor ConferencesYahoo Finance·Feb 26, 2026
- Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...Yahoo Finance·Feb 25, 2026
All 22 articles loaded
Price Data
Open$17.72
Previous Close$17.54
Day High$18.19
Day Low$17.23
52 Week High$30.98
52 Week Low$13.83
52-Week Range
$13.83$30.98
$17.85
Fundamentals
Market Cap$13.9B
P/E Ratio—
EPS$-1.59
Dividend Yield—
Dividend / Share—
ROE-2.7%
Profit Margin—
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding776.2M
About Summit Therapeutics Inc
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—